论文部分内容阅读
在2010年6月底第47届欧洲透析和移植大会上,PLANET研究结果的公布再次引起学术界对他汀类药物肾脏安全性问题的关注。其中PLANET1评估瑞舒伐他汀10～40mg/d及阿托伐他汀80mg/d对进展性肾病合并糖尿病患者肾脏的影响,而PLANET2则是评估瑞舒伐他汀10～40mg/d及阿托伐他汀40～80mg/d对进展性肾病无糖尿病患者肾脏的影响。两个研究随访时间为52周,观察指标有患者的尿蛋白/肌酐比值、肾小球滤过率(eGFR)以及其他指标的改变。PLANET研究结果发现,阿托伐
At the 47th European Dialysis and Transplant Conference in late June 2010, the publication of the PLANET study again raised the academic concern about the safety of statin kidney kidneys. Which PLANET1 assess rosuvastatin 10 ~ 40mg / d and atorvastatin 80mg / d on patients with progressive nephropathy combined with kidney effects of diabetes, and PLANET2 is the assessment of rosuvastatin 10 ~ 40mg / d and atorvastatin Effects of 40 ~ 80mg / d on Kidney in Patients with Progressive Nephropathy without. The follow-up time for both studies was 52 weeks, with changes in patients’ urinary protein / creatinine ratio, glomerular filtration rate (eGFR), and other parameters. PLANET findings found that attorney